Ray Dalio's BMRN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 375,683 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $20.35 M, representing 0.08% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2024, adding 160,166 shares. Largest reduction occurred in Q1 2024, reducing 187,604 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2014 | +48,400 | New Buy | 48,400 | $68.20 |
| Q2 2014 | -48,400 | Sold Out | 48,400 | $0.00 |
| Q3 2016 | +8,926 | New Buy | 8,926 | $92.54 |
| Q4 2016 | -8,926 | Sold Out | 8,926 | $0.00 |
| Q1 2021 | +13,438 | New Buy | 13,438 | $75.53 |
| Q2 2021 | +9,743 | Add 72.50% | 23,181 | $83.43 |
| Q3 2021 | -9,171 | Reduce 39.56% | 14,010 | $77.30 |
| Q4 2021 | -27 | Reduce 0.19% | 13,983 | $88.32 |
| Q1 2022 | +5,667 | Add 40.53% | 19,650 | $77.10 |
| Q2 2022 | +20,065 | Add 102.11% | 39,715 | $82.87 |
| Q3 2022 | +67,829 | Add 170.79% | 107,544 | $84.77 |
| Q4 2022 | -1,165 | Reduce 1.08% | 106,379 | $103.49 |
| Q1 2023 | +17,665 | Add 16.61% | 124,044 | $97.24 |
| Q2 2023 | +25,932 | Add 20.91% | 149,976 | $86.68 |
| Q3 2023 | +11,418 | Add 7.61% | 161,394 | $88.48 |
| Q4 2023 | +29,576 | Add 18.33% | 190,970 | $96.42 |
| Q1 2024 | -187,604 | Reduce 98.24% | 3,366 | $87.34 |
| Q2 2024 | +31,618 | Add 939.33% | 34,984 | $82.33 |
| Q3 2024 | +107,330 | Add 306.80% | 142,314 | $70.29 |
| Q4 2024 | +160,166 | Add 112.54% | 302,480 | $65.73 |
| Q1 2025 | -178,824 | Reduce 59.12% | 123,656 | $70.69 |
| Q2 2025 | +104,090 | Add 84.18% | 227,746 | $54.97 |
| Q3 2025 | +147,937 | Add 64.96% | 375,683 | $54.16 |
Ray Dalio's BioMarin Pharmaceutical Investment FAQs
Ray Dalio first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q1 2014, acquiring 48,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held BioMarin Pharmaceutical Inc. (BMRN) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2024, adding 302,480 shares worth $19.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 375,683 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $20.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.08% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 375,683 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.